Virus Antibody Candidates

Trellis has used its CellSpot technology to identify optimal antibodies from the immune system repertoires of healthy donors. Similar to Trellis' other indication candidates, these antibodies are extremely rare (<1 per 1 million memory B-cells) with high-affinity binding to homologous epitope regions across strain variants. Trellis has developed three antiviral antibody candidates against human cytomegalovirus (HCMV), infuenza (licensed to ContraFect Corporation in 2014), and respiratory syncytial virus (RSV). The first of our therapeutics will reach Phase I clinical trials by 2018.


Cytomegalovirus (CMV) Human mAb, TRL345

Problem Scope

Cytomegalovirus (CMV) is carried by more than half of the population and is the leading cause of serious complications in transplant recipients. CMV infection is a key risk factor in the first 3-6 months post-transplant, affecting 60-70% of patients.

In non-carriers, a CMV infection is a leading non-genetic cause of birth defects such as hearing loss, visual deficits, and cognitive delays, with an incident comparable to Down's syndrome.

Available antiviral drugs are too toxic for use in both of these indications, and drug resistance negatively impacts the efficacy for the most commonly used drugs.

CMV costs the US >$2B annually.

Seroprevalence shaded in blues. Congenital CMV denoted by colored circles
(Source: “’The Silent’ Global Burden of Congenital Cytomegalovirus.”

Trellis Innovation

Using CellSpot, Trellis screened over 5 million human memory B-cells (a subset of white blood cells) to discover TRL345, a high-affinity, native human antibody against the most conserved site on a CMV coat protein called glycoprotein B (gB), the surface protein associated with the virus’ entry into human cells. As described in published scientific papers, such antibodies are too rare within the human immune repertoire for reliable discovery by other techniques.

Neutralization studies in vitro showed that TRL345 is 10-fold more potent than previously described anti-gB antibodies and 50-fold more potent than Cytogam (HIG) (right). TRL345 fully neutralized 15 out of 15 clinical isolates, and protected all specialized cell types relevant to the human pathology. It was also fully protective in an ex vivo model of the human placenta grown as a tissue explant.

Since human CMV does not infect animals, making animal models not feasible, this model provides the most compelling support for likely utility in the congenital infection indication.


Pan-influenza Human mAb, CF404 - Licensed to Contrafect Corporation, Inc.

Problem Scope

Each year, 5-10% of the US population acquire the flu virus, costing the US $10.4B a year in direct medical expenses (Source: CDC).

On average, more than 200,000 patients within the US are hospitalized each year for seasonal influenza-associated infections.

In 2015, the CDC estimated that influenza vaccination prevented ~67K influenza-associated hospitalizations, but only ~50% of immunized elderly respond to the vaccine and produce neutralizing antibodies.

Emerging pandemic strains, such as the 2009 avian flu which infected 1 billion of the world’s population, remain a threat.

Trellis Innovation

Trellis has leveraged CellSpot's multiplexing assay to develop CF404, an antibody cocktail comprised of 3 mAbs. CF404 targets a region of the influenza virus that is highly conserved across multiple influenza strains.

This suggests potential efficacy against emergent mutant strains. As disclosed by ContraFect, clinical trials are projected to begin in 2018. (LINK)

Tamiflu efficacy drops sharply when given more than 24 hours post-infection. CF404 is still highly effective even when given 96 hours post-infection.


Respiratory Syncytial Virus (RSV) Human mAb, TRL3D3

Problem Scope

Respiratory Syncytial Virus (RSV) infects nearly all children worldwide by 2 to 3 years of age.

3-7% of children under the age of 2 are hospitalized annually in the US.

Globally, it is a leading cause of lower respiratory tract disease leading to 200,000 deaths and 3 million hospitalizations of young children annually

In the US, RSV is responsible for 18% of all respiratory illnesses in children under 5 years old, 20% of all hospitalizations, 18% of all emergency department visits, and 15% of all pediatric office visits. The cost of care for the ~125,000 infants hospitalized annually in the US is estimated at ~$1B.

Trellis Innovation

CellSpot allowed the discovery of a rare antibody, TRL3D3, specific to a conserved region on the G glycoprotein of respiratory syncytial virus.  TRL3D3 targets a highly-conserved portion of the G glycoprotein, while nearly all vaccine competitors are focused on the F glycoprotein due to its greater homology across strains and greater immunogenicity.

However, these treatments, including the currently available antibody treatment, palivizumab (Synagis), fail to address the fundamental pathology associated with the sabotage of the host immune response attributed to the viral G protein. Furthemore, Synagis is only approved for prophylaxis to protect high risk premature birth infants. Two decades of effort have failed to deliver an approved product for the much larger population of normal birth weight infants. TRL3D3 targets the RSV-G-Protein and blocks cell entry into airway epithelial cells, has direct antiviral activity, and reverses the viral sabotage of host immunity attributed to the secreted RSV-G-protein.

Experiments have shown TRL3DR to exhibit 100-fold greater potency than Synagis in vitro and greater efficacy in murine models at the same dose. TRL3D3 has also shown potent activity as an agent to restore airway function in a mouse RSV infection model that mimics clinical pathology.

As expected for a native human antibody targeting a viral protein with no human homolog, TRL3D3 showed no binding to a panel of human tissues and has been expressed at levels establishing feasibility of a commercially viable manufacturing process (3 g/L).

The currently available antibody treatment, palivizumab (Synagis), must be administered before infection.

In animal models, TRL3D3, demonstrated 100-fold greater efficacy than palivizumab, even when administered post-infection.

TRL3D3 is more effective at viral inhibition, demonstrated in a murine model through greater restoration of normal airway function (indicated by lowered airway resistance above) relative to Synagis, even 14 days after infection.